Terms: = Breast cancer AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Prognosis
101 results:
1. Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy.
Zhao F; Zhao C; Xu T; Lan Y; Lin H; Wu X; Li X
Front Immunol; 2023; 14():1245514. PubMed ID: 38111587
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of immune density, PD-L1, and cxcr4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.
Bagbudar S; Karanlık H; Cabioglu N; Bayram A; Tükenmez M; Aydıner A; Yavuz E; Onder S
Med Oncol; 2023 Dec; 41(1):18. PubMed ID: 38102446
[TBL] [Abstract] [Full Text] [Related]
3. Tamoxifen as a modulator of CXCL12-cxcr4-CXCR7 chemokine axis: A breast cancer and glioblastoma view.
Gonçalves TL; de Araújo LP; Pereira Ferrer V
Cytokine; 2023 Oct; 170():156344. PubMed ID: 37639844
[TBL] [Abstract] [Full Text] [Related]
4. HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of cxcr4 expression.
Takeda T; Tsubaki M; Genno S; Tokunaga K; Tanaka R; Nishida S
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37477145
[TBL] [Abstract] [Full Text] [Related]
5. cxcr4 expression is elevated in TNBC patient derived samples and Z-guggulsterone abrogates tumor progression by targeting CXCL12/cxcr4 signaling axis in preclinical breast cancer model.
Gupta N; Mohan CD; Shanmugam MK; Jung YY; Chinnathambi A; Alharbi SA; Ashrafizadeh M; Mahale M; Bender A; Kumar AP; Putti TC; Rangappa KS; Zhang X; Ahn KS; Sethi G
Environ Res; 2023 Sep; 232():116335. PubMed ID: 37290620
[TBL] [Abstract] [Full Text] [Related]
6. Genistein and coumestrol reduce MCF-7 breast cancer cell viability and inhibit markers of preferential metastasis, bone matrix attachment and tumor-induced osteoclastogenesis.
Al-Thamiree Mezban S; Fox SW
Arch Biochem Biophys; 2023 May; 740():109583. PubMed ID: 36967033
[TBL] [Abstract] [Full Text] [Related]
7. Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer cell migration.
Park C; Lee JW; Kim K; Seen DS; Jeong JY; Huh WK
Sci Rep; 2023 Feb; 13(1):1894. PubMed ID: 36732336
[TBL] [Abstract] [Full Text] [Related]
8. Association of chemokine (CXC motif) receptor 4 expression with lymphovascular invasion and lymph node metastasis of invasive breast cancer.
Mamonto L; Nelwan BJ; Sungowati NK; Miskad UA; Cangara MH; Zainuddin AA
Breast Dis; 2022; 41(1):447-453. PubMed ID: 36617771
[TBL] [Abstract] [Full Text] [Related]
9. Potential Application of Leelamine as a Novel Regulator of Chemokine-Induced Epithelial-to-Mesenchymal Transition in breast cancer Cells.
Jung YY; Um JY; Sethi G; Ahn KS
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077241
[TBL] [Abstract] [Full Text] [Related]
10. Demystifying the cxcr4 conundrum in cancer biology: Beyond the surface signaling paradigm.
Nengroo MA; Khan MA; Verma A; Datta D
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188790. PubMed ID: 36058380
[TBL] [Abstract] [Full Text] [Related]
11. cancer-Associated Exosomal CBFB Facilitates the Aggressive Phenotype, Evasion of Oxidative Stress, and Preferential Predisposition to Bone Prometastatic Factor of breast cancer Progression.
Hsu CH; Ma HP; Ong JR; Hsieh MS; Yadav VK; Yeh CT; Chao TY; Lee WH; Huang WC; Kuo KT; Fong IH; Lin CC; Su CM
Dis Markers; 2022; 2022():8446629. PubMed ID: 35903297
[TBL] [Abstract] [Full Text] [Related]
12. An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy.
Blaye C; Darbo É; Debled M; Brouste V; Vélasco V; Pinard C; Larmonier N; Pellegrin I; Tarricone A; Arnedos M; Commeny J; Bonnefoi H; Larmonier C; MacGrogan G
ESMO Open; 2022 Aug; 7(4):100502. PubMed ID: 35759853
[TBL] [Abstract] [Full Text] [Related]
13. The CXCL12/cxcr4/ACKR3 Signaling Axis Regulates PKM2 and Glycolysis.
Luker KE; Luker GD
Cells; 2022 May; 11(11):. PubMed ID: 35681470
[TBL] [Abstract] [Full Text] [Related]
14. Identification of FOXM1 and cxcr4 as key genes in breast cancer prevention and prognosis after intermittent energy restriction through bioinformatics and functional analyses.
Li L; Chen L; Yu L; Zhang J; Chen L
Adipocyte; 2022 Dec; 11(1):301-314. PubMed ID: 35481418
[TBL] [Abstract] [Full Text] [Related]
15. The Embryonic Key Pluripotent Factor NANOG Mediates Glioblastoma Cell Migration via the SDF1/cxcr4 Pathway.
Sánchez-Sánchez AV; García-España A; Sánchez-Gómez P; Font-de-Mora J; Merino M; Mullor JL
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638956
[TBL] [Abstract] [Full Text] [Related]
16. Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative breast cancer.
Harris RJ; Cheung A; Ng JCF; Laddach R; Chenoweth AM; Crescioli S; Fittall M; Dominguez-Rodriguez D; Roberts J; Levi D; Liu F; Alberts E; Quist J; Santaolalla A; Pinder SE; Gillett C; Hammar N; Irshad S; Van Hemelrijck M; Dunn-Walters DK; Fraternali F; Spicer JF; Lacy KE; Tsoka S; Grigoriadis A; Tutt ANJ; Karagiannis SN
Cancer Res; 2021 Aug; 81(16):4290-4304. PubMed ID: 34224371
[TBL] [Abstract] [Full Text] [Related]
17. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy.
Correia AL; Guimaraes JC; Auf der Maur P; De Silva D; Trefny MP; Okamoto R; Bruno S; Schmidt A; Mertz K; Volkmann K; Terracciano L; Zippelius A; Vetter M; Kurzeder C; Weber WP; Bentires-Alj M
Nature; 2021 Jun; 594(7864):566-571. PubMed ID: 34079127
[TBL] [Abstract] [Full Text] [Related]
18. cxcr4 intracellular protein promotes drug resistance and tumorigenic potential by inversely regulating the expression of Death Receptor 5.
Nengroo MA; Maheshwari S; Singh A; Verma A; Arya RK; Chaturvedi P; Saini KK; Singh AK; Sinha A; Meena S; Gupta A; Mishra A; Sarkar J; Datta D
Cell Death Dis; 2021 May; 12(5):464. PubMed ID: 33966046
[TBL] [Abstract] [Full Text] [Related]
19. Bone marrow cells are differentiated into MDSCs by BCC-Ex through down-regulating the expression of cxcr4 and activating STAT3 signalling pathway.
Liu QW; Chen Y; Li JY; Xiao L; Zhang WJ; Zhao JL; Gu HC; Wu HY; Zuo GS; Deng KY; Xin HB
J Cell Mol Med; 2021 Jun; 25(12):5497-5510. PubMed ID: 33955151
[TBL] [Abstract] [Full Text] [Related]
20. miR-34a and miR-200c Have an Additive Tumor-Suppressive Effect on breast cancer Cells and Patient prognosis.
Mansoori B; Silvestris N; Mohammadi A; Khaze V; Baghbani E; Mokhtarzadeh A; Shanehbandi D; Derakhshani A; Duijf PHG; Baradaran B
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33673143
[TBL] [Abstract] [Full Text] [Related]
[Next]
